These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22256444)

  • 1. Atypical fractures on long term bisphosphonates therapy.
    Hussein W; Cunningham C; Logan H; Fallon C; Murphy S
    Ir Med J; 2011; 104(10):308, 310. PubMed ID: 22256444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].
    Soen S
    Clin Calcium; 2011 Oct; 21(10):1543-6. PubMed ID: 21960242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
    Angthong C; Angthong W
    J Med Assoc Thai; 2011 Dec; 94 Suppl 7():S214-20. PubMed ID: 22619933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
    Schneider JP
    Geriatrics; 2009 Jan; 64(1):18-23. PubMed ID: 19256578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
    Bize R; Lamy O; Peytremann-Bridevaux I
    Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.
    Huang HT; Kang L; Huang PJ; Fu YC; Lin SY; Hsieh CH; Chen JC; Cheng YM; Chen CH
    Menopause; 2012 Dec; 19(12):1360-3. PubMed ID: 22968250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rare case of a bisphosphonate-induced peri-prosthetic femoral fracture.
    Cross MB; Nam D; van der Meulen MC; Bostrom MP
    J Bone Joint Surg Br; 2012 Jul; 94(7):994-7. PubMed ID: 22733959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Alendronate for treatment of osteoporoses].
    Harada A
    Nihon Rinsho; 2009 May; 67(5):943-7. PubMed ID: 19432114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.
    Chiu WY; Lee JJ; Tsai KS
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E723-6. PubMed ID: 23471975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long term effects of raloxifen on the bones].
    Eiken PA
    Ugeskr Laeger; 2008 Jan; 170(4):224-6. PubMed ID: 18282451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
    Cole RE
    Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy--a case report.
    Sayed-Noor AS; Sjödén GO
    Acta Orthop; 2008 Aug; 79(4):565-7. PubMed ID: 18766492
    [No Abstract]   [Full Text] [Related]  

  • 15. Management after first-line antiresorptive treatment for postmenopausal osteoporosis.
    Paccou J
    Joint Bone Spine; 2016 Jul; 83(4):373-5. PubMed ID: 26992951
    [No Abstract]   [Full Text] [Related]  

  • 16. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.
    Sánchez A; Blanco R
    Osteoporos Int; 2017 Mar; 28(3):1145-1147. PubMed ID: 27866217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
    Gold DT; Martin BC; Frytak JR; Amonkar MM; Cosman F
    Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral low-energy sequential femoral shaft fractures in patients on long-term bisphosphonate therapy.
    Çakmak S; Mahiroğulları M; Keklikçi K; Sarı E; Erdik B; Rodop O
    Acta Orthop Traumatol Turc; 2013; 47(3):162-72. PubMed ID: 23748615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
    Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features.
    Chan SS; Rosenberg ZS; Chan K; Capeci C
    AJR Am J Roentgenol; 2010 Jun; 194(6):1581-6. PubMed ID: 20489100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.